Form 4: Kalaris Therapeutics Director Acquires Stock Options Following Merger
SEC Form 4 Filing
Andrew Oxtoby, a director and officer of Kalaris Therapeutics, acquired stock options as a result of the merger with Kalaris Tx, Inc.
Summary
- Andrew Oxtoby, President and CEO of Kalaris Therapeutics, Inc., filed a Form 4 detailing changes in beneficial ownership.
- The filing reports the acquisition of stock options (right to buy) with an exercise price of $0.85.
- These options were assumed in connection with the merger between Kalaris Therapeutics, Inc. and Kalaris Tx, Inc., which was completed under the Agreement and Plan of Merger dated November 7, 2024.
- The acquired options cover 476,611 shares of common stock.
- The options vest over four years beginning March 4, 2024, with 25% vesting on March 4, 2025, and the remainder vesting monthly thereafter.
- The expiration date for the options is May 27, 2034.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to a merger. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about insider transactions.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be an indicator of management's confidence in the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 2024-03-04 | Vesting commencement date for the stock options. |
| 2024-11-07 | Date of the Agreement and Plan of Merger between Kalaris Therapeutics and Kalaris Tx, Inc. |
| 2025-03-04 | 25% of the stock options vested. |
| 2025-03-18 | Date of the reported transaction (acquisition of stock options). |
| 2034-05-27 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.